Jefferies Reiterates Buy on Pfizer (PFE) Post Allergen Collapse, PT Trimmed to $39

JPMorgan Resumes Pfizer (PFE) at Overweight

JPMorgan resumed coverage on Pfizer (NYSE: PFE) with an Overweight rating and a price target of $38.00.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $32.93 yesterday.

Allergen's (AGN) Price Target Reduced to $282 at Deutsche Bank

Deutsche Bank maintained a Buy rating on Allergen (NYSE: AGN) but lowered its price target to $282.00 (from $339.00). Earlier its merger with Pfizer (NYSE: PFE) was terminated.

"It is important to note that our estimates and... More

Allergan (AGN) Affirms Termination of Pfizer (PFE) Merger; Affirms Strength as Standalone Company

Allergan plc (NYSE: AGN) announced that its merger agreement with Pfizer (NYSE: PFE) has been terminated by mutual agreement, effective . In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.

Allergan reiterated its compelling standalone growth profile and strategy following the announced termination of the combination of the two companies. Allergan is positioned to drive strong, sustainable growth powered by leading franchises, new potential blockbuster product launches and unmatched pipeline.

"While we... More

Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)

Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change... More